EGFR-TKIs 在晚期EGFR受体突变肺鳞癌患者中的临床应用

目的:探讨表皮生长因子受体酪氨酸激酶抑制剂（epidermal growth factor receptor tyrosine kinase inhibitors，EGFR-TKIs）对具有表皮生长因子受体（epidermal growth factor receptor ，EGFR）突变的晚期肺鳞癌患者临床疗效。方法:回顾性分析首都医科大学附属北京胸科医院2010年1 月至2016年7 月收治的2 317 肺鳞癌患者，筛选出有明确随访记录的7 例确诊具有EGFR 突变的肺鳞癌患者，使用EGFR-TKI 如吉非替尼、厄洛替尼治疗，直至疾病进展（progressive disease ，PD）。 结果:使用EGFR-TKI 治疗后，患者客观缓解率（objectire response rate ，ORR ）42.9% ，疾病控制率（disease control rate ，DCR ）100%（7/ 7），中位无进展生存期6.1 个月。结论:EGFR-TKI 对EGFR 突变的肺鳞癌患者具有一定临床疗效。但本研究病例数少仅有7 例，亟需更多的病例来进行补充研究及验证上述结论。 

Clinical efficacy of EGFR-TKIs for advanced squamous-cell lung cancer patients with EGFR mutations

Abstrac Objective:To investigate the clinical efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in the treatment of squamous-cell lung cancer patients with EGFR mutations. Methods:We screened out seven patients who were diag-nosed with EGFR mutations and received EGFR-TKIs, such as gifitinib or erlotinib, from 2,317 squamous-cell lung cancer patients treat-ed at the Beijing Chest Hospital from January 2010 to July 2016. Results:After using EGFR-TKIs, the objective response rate was 42.9%, the disease control rate was 100%, and the median progression-free survival was 6.1 months. Conclusion:EGFR-TKIs exert a certain clinical curative effect on patients with EGFR mutations in squamous-cell lung cancer. However, given that only seven cases are pre-sented in this research group, more cases are needed for further research to verify the above conclusion.